BlenderBottle revolutionizes portable nutrition
PLEASANT GROVE, Utah — BlenderBottle Company today announced a new portable stacking device designed to carry powders, pills, snacks and more while traveling.
The GoStak is a system of durable interlocking jars. As an innovative alternative to messy baggies and bulky containers, it provides a way to carry protein powders, meal replacement ingredients, vitamins, supplements, flavored drink mixes, energy powders and electrolyte supplements. It can also be used for condiments, baby formula, toddler snacks and more.
The GoStak is made of durable, stain- and odor-resistant Eastman Tritan. A unique Twist n’ Lock system secures the jars together with a quick twist; and a secure seal ensures worry-free portability. Designed to work with the BlenderBottle SportMixer and Classic products, the GoStak fits inside the bottles for compact traveling. The inclusion of a removable carrying handle also makes it a snap to clip to your bag or purse and take anywhere.
“We designed the GoStak to complement and work in tandem with our other BlenderBottle products,” said Steve Sorensen, inventor and CEO of BlenderBottle. “So many people are taking nutritional supplements on the go, but have to resort to messy baggies or bulky containers. Since the GoStak fits right inside the BlenderBottle shaker cups, people can fill their GoStak jars, lock them together, and pop them in their BlenderBottle as they head out the door.”
Like all BlenderBottle products, the GoStak is BPA-free. The GoStak system features four different jar sizes (larger-diameter jars coming later this year), each able to lock interchangeably with others, allowing users to mix and match to fit their needs. The entire system is dishwasher safe.
The BlenderBottle GoStak is available in a variety of colors in the following configurations: 4 Pak Assorted (MSRP $12.99); 2 Pak 150 cc (MSRP $9.99); 3 Pak 100 cc (MSRP $9.99); 3 Pak 60 cc (MSRP $8.99); 4 Pak 40 cc (MSRP $8.99). The GoStak is available for purchase at blenderbottle.com, as well as several national retailers.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.
Mallinckrodt collects unused medications in St. Louis
ST. LOUIS — Medical products manufacturer Covidien’s pharmaceutical division is expanding an initiative to collect unused and unwanted medications.
Mallinckrodt said it would expand communities’ access to drug take-back collection boxes and promote safe disposal practices, installing lock boxes in three police stations around St. Louis. The company said it purchased the boxes under a collaboration with the National Association of Drug Diversion Investigators and also would provide a grant to help incinerate the medications that are collected.
"We’re proud to work with the St. Louis Police Department and the Missouri Prescription Pill and Drug Disposal on these efforts," Mallinckrodt president Mark Trudeau said. "Mallinckrodt has been a proud member of the St. Louis community since 1867, and we are experts at managing the complex nature of controlled substances."
PhRMA report lists 241 drugs under development for blood cancer
WASHINGTON — More than 200 drugs for blood cancers are under development, according to a new report by a drug industry trade group.
The Pharmaceutical Research and Manufacturers of America said 241 medicines were in clinical development or under review by the Food and Drug Administration, including 98 for lymphoma, 97 for leukemia, 52 for multiple myeloma and 24 for malignancies of the bone marrow, blood and lymph nodes.
"Complex diseases like blood cancer provide a daunting healthcare challenge for patients, their doctors and the biopharmaceutical research ecosystem," PhRMA president and CEO John Castellani said. "The more than 240 medicines in development for leukemia, lymphoma and other forms of blood cancer reflect biopharmaceutical research companies’ commitment to build on progress to date and help bring new treatment options to patients."
The group noted that according to the Leukemia and Lymphoma Society, the five-year survival rate for non-Hodgkin lymphoma was 40% in the early 1960s, and the rate for leukemia was 14%; by the last decade, those rates had climbed respectively to 86% and 57%, thanks to improvements in treatment.
In other news, the group said it had raised more than $100,000 to establish a new grant for blood cancer research and that 60 of its employees would participate in this Sunday’s inaugural Nike Women Half Marathon D.C. to benefit the Leukemia and Lymphoma Society’s Team in Training program.